Clinical trial
Chemoembolization and Bevacizumab in Treating Patients With Liver Cancer That…
NCT00049322 · Jonsson Comprehensive Cancer Center, Other · Completed
Key facts
| NCT number | NCT00049322 |
|---|---|
| Title | Chemoembolization and Bevacizumab in Treating Patients With Liver Cancer That Cannot Be Removed With Surgery |
| Official title | A Phase II Study Of rhuMAb VEGF (BEVACIZUMAB) In Patients With Hepatocellular Carcinoma Receiving Chemoembolization |
| Lead sponsor | Jonsson Comprehensive Cancer Center, Other |
| Collaborators | National Cancer Institute (NCI) NIH Genentech, Inc. Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Liver Cancer |
| Intervention type | Biological |
| Interventions | bevacizumab |
| Enrollment | 30 |
| Start date | Jun 1, 2003 |
| Primary completion | Feb 1, 2012 |
| Completion | Feb 1, 2012 |
| First posted | Jan 27, 2003 |
| Last update posted | Sep 1, 2020 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: